OBJECTIVE: To assess patient-reported efficacy and safety of ramelteon in Japanese
patients with chronic insomnia. METHODS: Randomized, double-blind, placebo-controlled …

OBJECTIVE: To evaluate the safety of ramelteon, a highly selective MT1/MT2 melatonin
receptor agonist, during 24weeks' treatment of Japanese patients with chronic insomnia …

This randomized, double-blind, placebo-controlled study assessed the efficacy and safety of
ramelteon 4 and 8 mg in Japanese adults with chronic insomnia. A secondary objective was …

The aim of this study was to evaluate the efficacy and safety of ramelteon 4, 8, 16 or 32 mg
and placebo in Japanese patients with chronic insomnia using a randomized, double-blind …

Abstract Study Objectives: Long-duration (≥ 6 months) polysomnographic studies of
insomnia medications are lacking. This study evaluated the long-term efficacy of ramelteon …

BACKGROUND AND PURPOSE: To evaluate the efficacy, safety, and dose response of
Ramelteon, a novel highly selective MT1/MT2 receptor agonist, in patients with chronic …

BACKGROUND AND PURPOSE: To assess the efficacy and safety of ramelteon, a selective
MT1/MT2 receptor agonist, for chronic insomnia treatment. PATIENTS AND METHODS …

Objective: To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor agonist) in
subjects with chronic primary insomnia. Methods: Randomized, multicenter, double-blind …

Objective: Ramelteon is an MT1/MT2 melatonin receptor agonist indicated for the treatment
of insomnia characterized by difficulty with sleep onset. In previous clinical studies …

Background: Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …